- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05221931
Drug-Coated Balloon in Patients With High Bleeding Risk (DCB-HBR)
Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk (DCB-HBR Trial)
DCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial.
The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of de-novo coronary lesion under intravascular imaging-guided optimization in patients with high bleeding risk (HBR).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Second-generation drug-eluting stent (DES) is the standard of care for patients with coronary artery disease who are deemed eligible for percutaneous coronary intervention (PCI). Despite many advantages, DES inevitably accompanies disadvantages such as the occurrence of late stent thrombosis and the need for maintaining dual antiplatelet (DAPT) for certain period due to permanent vascular implant, which leads to both increased ischemic and bleeding events.
As an alternative to DES, drug-coated balloon (DCB), a novel treatment strategy, which has benefit of having shorter DAPT maintenance duration due to the absence of scaffolds and polymers, has been introduced. Based on meta-analysis based on many randomized clinical trials (RCT), its use has been established in in-stent restenosis of bare-metal stents (BMS) and DES. Furthermore, recently published RCTs demonstrated efficacy and safety of DCB in de-novo coronary lesions in small vessels. However, studies exploring the feasibility of DCB in de-novo coronary lesions are limited. In particular, there are scarce data comparing DCB with DES in patients with high bleeding risk (HBR), a situation in which long-term maintenance of DAPT is a clinical dilemma. In the previous two RCTs, DCB showed noninferiority to DES in lesions in large vessels. Nevertheless, these studies were conducted in non-HBR patients and the number of participated patients was insufficient. In another RCT, only patients with HBR were included, but the efficacy of DCB was compared with BMS not DES.
Recently, studies have proved short term (1-3 months) DAPT has comparable efficacy to longer DAPT in HBR patients using latest second-generation DES. On this background, this trial aims to compare clinical outcomes between DCB and DES in de-novo coronary lesions in large vessels in patients with HBR receiving short term DAPT.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Joo Myung Lee, MD, PhD
- Phone Number: 82-2-3410-3391
- Email: drone80@hanmail.net
Study Contact Backup
- Name: Min-Jeong Seok
- Phone Number: 82-2-3410-3391
- Email: smg0492@naver.com
Study Locations
-
-
-
Ansan, Korea, Republic of
- Recruiting
- Korea University Ansan Hospital
-
Contact:
- Sunwon Kim, MD, PhD
- Email: sunwon11@hanmail.net
-
Principal Investigator:
- Sunwon Kim, MD, PhD
-
Cheongju, Korea, Republic of
- Recruiting
- Chungbuk National University
-
Contact:
- Jang-Whan Bae, MD, PhD
- Email: drcorazon@hanmail.net
-
Principal Investigator:
- Jang-Whan Bae, MD, PhD
-
Daegu, Korea, Republic of
- Recruiting
- Keimyung University Dongsan Hospital
-
Contact:
- Hyuck-Jun Yoon, MD, PhD
- Email: hippsons@gmail.com
-
Principal Investigator:
- Hyuck-Jun Yoon, MD, PhD
-
Gangneung, Korea, Republic of
- Recruiting
- Gangneung Asan Hospital, University of Ulsan College of Medicine
-
Contact:
- Hanbit Park, MD, PhD
- Email: phb8012@gmail.com
-
Principal Investigator:
- Hanbit Park, MD, PhD
-
Gwangju, Korea, Republic of
- Recruiting
- Chonnam National University Hospital
-
Contact:
- Seung Hun Lee, MD, PhD
- Email: lsh8602@naver.com
-
Principal Investigator:
- Seung Hun Lee, MD, PhD
-
Contact:
- Young Joon Hong, MD, PhD
- Email: hyj200@hanmail.net
-
Principal Investigator:
- Young Joon Hong, MD, PhD
-
Gwangmyeong, Korea, Republic of
- Recruiting
- Chung-Ang University Gwangmyeong Hospital
-
Contact:
- Sang Yeub Lee, MD, PhD
- Email: louisahj@gmail.com
-
Principal Investigator:
- Sang Yeub Lee, MD, PhD
-
Incheon, Korea, Republic of
- Recruiting
- Inha University Hospital
-
Contact:
- Sang Don Park, MD, PhD
- Email: denki1@inha.ac.kr
-
Principal Investigator:
- Sang Don Park, MD, PhD
-
Jinju, Korea, Republic of
- Recruiting
- Gyeongsang National University Hospital
-
Contact:
- Jin-Sin Koh, MD, PhD
- Email: kjs0175@gmail.com
-
Contact:
- Hangyul Kim, MD, PhD
- Email: 13medicine@naver.com
-
Principal Investigator:
- Hangyul Kim, MD, PhD
-
Principal Investigator:
- Jin-Sin Koh, MD, PhD
-
Seongnam-si, Korea, Republic of
- Recruiting
- Seoul National University Bundang Hospital
-
Contact:
- Ki-Hyun Jeon, MD, PhD
- Email: imcardio@gmail.com
-
Principal Investigator:
- Ki-Hyun Jeon, MD, PhD
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Principal Investigator:
- Joo Myung Lee, MD, MPH, PhD
-
Contact:
- David Hong, MD
- Phone Number: 82-2-3410-2575
- Email: hongdawi@naver.com
-
Sub-Investigator:
- Ki Hong Choi, MD, PhD
-
Contact:
- Joo Myung Lee, MD, MPH, PhD
- Phone Number: 82-2-3410-2575
- Email: drone80@hanmal.net
-
Sub-Investigator:
- Taek Kyu Park, MD, PhD
-
Sub-Investigator:
- Jeong Hoon Yang, MD, PhD
-
Sub-Investigator:
- Young Bin Song, MD, PhD
-
Sub-Investigator:
- Joo-Yong Hahn, MD, PhD
-
Seoul, Korea, Republic of
- Recruiting
- Seoul St. Mary's Hospital, The Catholic University of Korea
-
Contact:
- Eun Ho Choo, MD, PhD
- Email: cmcchu@catholic.ac.kr
-
Contact:
- Kwan Yong Lee, MD, PhD
- Email: kyle210@naver.com
-
Principal Investigator:
- Eun Ho Choo, MD, PhD
-
Sub-Investigator:
- Kwan Yong Lee, MD, PhD
-
Uijeongbu, Korea, Republic of
- Recruiting
- The Catholic University of Korea, Uijeongbu St. Mary's Hospital
-
Contact:
- Seonghyeon Bu, MD, PhD
- Email: buseonghyeon@gmail.com
-
Contact:
- Chan Joon Kim, MD, PhD
- Email: godandsci@naver.com
-
Principal Investigator:
- Seonghyeon Bu, MD, PhD
-
Principal Investigator:
- Chan Joon Kim, MD, PhD
-
Wonju, Korea, Republic of
- Recruiting
- Wonju Severance Christian Hospital
-
Contact:
- Sung Gyun Ahn, MD, PhD
- Email: sgahn@yonsei.ac.kr
-
Principal Investigator:
- Sung Gyun Ahn, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject must be at least 19 years of age
- Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.
- Patients with at least one lesion with greater than 50% diameter stenosis or fractional flow reserve ≤0.80 requiring revascularization in de-novo coronary artery of reference vessel size ≥2.25 mm
- Patients with high bleeding risk: one or more of the criteria listed (1) Adjunctive oral anticoagulation treatment planned to continue after PCI (2) Age ≥ 75 years old (3) Baseline Hemoglobin <11 g/dl (or anemia requiring transfusion during the 4 weeks prior to randomization) (4) Any prior intra-cerebral bleed (5) Stroke at any time or transient ischemic attack in the previous 6 months. (6) Hospital admission for bleeding during the prior 12 months (7) Non skin cancer diagnosed or treated < 3 years (8) Planned daily NSAID (other than aspirin) or steroids for >30 days after PCI (9) Planned surgery that would require interruption of DAPT (within next 12 months) (10) Renal failure defined as calculated creatinine clearance <40 ml/min or on dialysis (11) Hematological disorders (platelet count <100,000/mm3 or any coagulation disorder) (12) Severe chronic liver disease defined as patients who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice (13) Expected non-compliance to prolonged DAPT for other medical reasons
Exclusion Criteria:
- Patients unable to provide consent
- Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents
- Patients with angiographic findings of (1) Left main coronary artery disease (2) In-stent restenosis is the cause of target lesion (3) Target lesion in bypass graft (4) True bifurcation lesion that requires upfront 2-stenting
- Patients who have non-cardiac co-morbid conditions with life expectancy <2 year
- Patients who may result in protocol non-compliance (site investigator's medical judgment)
- Patients with cardiogenic shock or cardiac arrest
- Patients with severe left ventricular systolic dysfunction (ejection fraction <30%)
- Patients with severe valvular heart disease requiring open heart surgery
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: DES group
Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography. In DES group, latest second-generation DES will be used (Ultimaster Tansei) during the index procedure |
1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent [Boston Scientific, USA], Prevail [Medtronic, USA], or SeQuent Please, SeQuent Please NEO [B-Braun, Germany])
|
Experimental: DCB group
Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography. In DCB group, Agent (Boston Scientific, USA), Prevail (Medtronic, USA), or SeQuent Please, SeQuent Please NEO (B-Braun, Germany) will be used during the index procedure. |
1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent [Boston Scientific, USA], Prevail [Medtronic, USA], or SeQuent Please, SeQuent Please NEO [B-Braun, Germany])
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target vessel failure (TVF)
Time Frame: 2 years from last patient enrollment
|
a composite of cardiovascular death, target-vessel myocardial infarction (MI), and clinically indicated target-vessel revascularization (TVR)
|
2 years from last patient enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular death
Time Frame: 2 years from last patient enrollment
|
Cardiovascular death
|
2 years from last patient enrollment
|
All-cause death
Time Frame: 2 years from last patient enrollment
|
All-cause death
|
2 years from last patient enrollment
|
Target-vessel MI
Time Frame: 2 years from last patient enrollment
|
Target-vessel MI
|
2 years from last patient enrollment
|
Non-fatal MI
Time Frame: 2 years from last patient enrollment
|
Non-fatal MI
|
2 years from last patient enrollment
|
Clinically indicated target-lesion revascularization (TLR)
Time Frame: 2 years from last patient enrollment
|
Clinically indicated target-lesion revascularization (TLR)
|
2 years from last patient enrollment
|
Clinically indicated TVR
Time Frame: 2 years from last patient enrollment
|
Clinically indicated TVR
|
2 years from last patient enrollment
|
Any revascularization
Time Frame: 2 years from last patient enrollment
|
Any revascularization
|
2 years from last patient enrollment
|
Vessel or stent thrombosis
Time Frame: 2 years from last patient enrollment
|
definite or probable by Academic Research Consortium (ARC) definition
|
2 years from last patient enrollment
|
Cardiovascular death or target-vessel MI
Time Frame: 2 years from last patient enrollment
|
Cardiovascular death or target-vessel MI
|
2 years from last patient enrollment
|
All-cause death or non-fatal MI
Time Frame: 2 years from last patient enrollment
|
All-cause death or non-fatal MI
|
2 years from last patient enrollment
|
Target lesion failure (TLF)
Time Frame: 2 years from last patient enrollment
|
a composite of cardiovascular death, target-vessel MI, and clinically indicated TLR
|
2 years from last patient enrollment
|
Cardiovascular death, target-vessel MI, or vessel or stent thrombosis
Time Frame: 2 years from last patient enrollment
|
Cardiovascular death, target-vessel MI, or vessel or stent thrombosis
|
2 years from last patient enrollment
|
All-cause death, non-fatal MI, or TVR
Time Frame: 2 years from last patient enrollment
|
All-cause death, non-fatal MI, or TVR
|
2 years from last patient enrollment
|
Major bleeding (Major secondary endpoint)
Time Frame: 2 years from last patient enrollment
|
BARC type 2, 3 or 5 bleeding
|
2 years from last patient enrollment
|
Major bleeding
Time Frame: 2 years from last patient enrollment
|
The Thrombolysis in Myocardial Infarction (TIMI) major bleeding
|
2 years from last patient enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joo Myung Lee, MD, PhD, Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DCBHBR2021-12-111-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Percutaneous coronary intervention
-
Mid and South Essex NHS Foundation TrustImperial College LondonRecruitingStable Angina | Chronic Total Occlusion of Coronary ArteryUnited Kingdom
-
University Hospital, SaarlandCompletedAcute Myocardial InfarctionGermany
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCoronary Artery DiseaseChina
-
University Hospital of PatrasCompletedCoronary Artery Bypass SurgeryGreece
-
Yonsei UniversityUnknownCoronary Artery Disease | Stable Angina | Unstable AnginaKorea, Republic of
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Herlev and Gentofte HospitalUnknownCoronary Heart Disease | Ischemic Heart Disease | Stable AnginaDenmark
-
RobocathCompletedCoronary Artery Disease | Percutaneous Coronary InterventionFrance, Belgium, Luxembourg, Netherlands
-
University College, LondonNational Institute for Cardiovascular Outcomes Research; British Cardiovascular... and other collaboratorsCompletedPercutaneous Coronary InterventionUnited Kingdom
-
Niels Ramsing HolmJohnson & JohnsonUnknown